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Abstract
SUMO (small ubiquitin-related modifier) is a reversible post-translational protein modifier that alters the localization, activity,
or stability of proteins to which it is attached. Many enzymes participate in regulated SUMO-conjugation and SUMO-
deconjugation pathways. Hundreds of SUMO targets are currently known, with the majority being nuclear proteins.
However, the dynamic and reversible nature of this modification and the large number of natively sumoylated proteins in
eukaryotic proteomes makes molecular dissection of sumoylation in eukaryotic cells challenging. Here, we have
reconstituted a complete mammalian SUMO-conjugation cascade in Escherichia coli cells that involves a functional SUMO E3
ligase, which effectively biases the sumoylation of both native and engineered substrate proteins. Our sumo-engineered
E. coli cells have several advantages including efficient protein conjugation and physiologically relevant sumoylation
patterns. Overall, this system provides a rapid and controllable platform for studying the enzymology of the entire
sumoylation cascade directly in living cells.
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Introduction
Sumoylation is a eukaryotic post-translational modification that
involves the covalent conjugation of the 11-kDa SUMO (small
ubiquitin-related modifier) protein to a lysine residue in a target
protein (for recent reviews of the sumoylation mechanism and its
implications see [1,2,3,4,5,6]). Cellular processes in which
sumoylation is involved include cellular trafficking, channel and
receptor regulation, regulation of transcription-factor activity,
DNA repair and replication, chromosome dynamics, mRNA
processing and metabolism, cellular replication, and cross-talk
with ubiquitination. The mechanism of SUMO attachment
resembles other ubiquitin-like conjugation pathways. Briefly,
mature SUMO is first activated by a heterodimeric SUMO-
activating enzyme, E1, before passing to the SUMO-conjugating
enzyme, E2. Only one E2 appears to exist in most well studied
organisms including human, yeast, rat, and mouse. Unlike with
ubiquitination, sumoylation may proceed in an E3-independent
manner. This notion is based on the observation that binding of
the E2 Ubc9 to the consensus sequence Y-K-X-E (where Y is
a hydrophobic residue and X is an arbitrary residue) present in
a target protein is sufficient for sumoylation [7,8,9]. Furthermore,
grafting of this consensus sequence to a protein not normally
sumoylated will result in its sumoylation [8,10,11].
Given the apparent E3-independent nature of sumoylation, the
existence of SUMO E3 ligases was initially challenged [12],
although evidence hinted at their existence [6]. The involvement
of E3 ligases in sumoylation has now been demonstrated
[13,14,15]. However, while an E3 can enhance target sumoylation
[10,13,15,16], its role in substrate specificity and lysine selection
remains debated. The crystal structure of SUMO-RanGAP1-
Ubc9-Nup358 complex suggests the E3 merely aligns the E2-
SUMO pair for optimal E2 binding and SUMO transfer without
itself binding the target protein [17]. Interactions between the
target protein and E3 appear to augment efficiency, but
sumoylation depends solely upon E2 binding [17]. Furthermore,
individual genetic knockout of the mammalian SUMO E3 ligases
PIAS1 [18], PIASy [19], and PIASx [20] in mice does not affect
global sumoylation patterns. Similarly in yeast, knockout of the E3
Siz2 does not affect global sumoylation, although the knockout of
the E3 Siz1 attenuates robustness [13]. Further studies in yeast
examining sumoylation of individual proteins confirm this trend in
overlapping E3 function [10]. Differences in local concentrations
rather than differences in target recognition may be the
mechanism whereby E3 specificity is manifested in vivo but is
absent in vitro [10].
Importantly, SUMO E3 ligases are not dispensable in the
cellular context as the knockout of every E3 is lethal [10].
Furthermore, emerging evidence suggests that the E3 may play
a role in target specificity. Several proteins are modified at
nonconsensus sequences [4] and an E3 ligase, not an E2, may be
responsible for this modification. For example, Siz1 is required for
sumoylation of PCNA’s nonconensus K164 site [21]. Several
studies have confirmed that the PINIT domain of the E3 is solely
responsible for this K164 lysine specificity [10,22]. Further, E3s
tend to bias the particular SUMO isoform that is attached to the
target protein [23].
Several groups have reconstituted E3-independent sumoylation
cascades in E. coli [11,24,25]. These sumo-engineered E. coli
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sumoylated protein in eukaryotic cells tend to be low [3]. Thus,
purifying quantifiable amounts from these cells is difficult, whereas
obtaining ample yields for study from E. coli is typically
straightforward. Second, because E. coli lacks an endogenous
sumoylation system, the pathway may be isolated up to the point
of the E2 for study. However, these systems are not without
shortcomings. E3-independent sumoylation itself occurs at quan-
tifiable levels only for protein concentrations far exceeding
physiological levels. While proteins are clearly sumoylated, the
physiological relevance of the modified proteins is unclear. For
example, Mencı ´a and de Lorenzo observed attachment of poly-
SUMO-1 chains to target proteins in E. coli [11]. Because SUMO-
1 lacks the consensus sequence present on SUMO-2 and SUMO-3
[26], it is not believed to homo-polymerize. However, more recent
in vitro studies have shown that SUMO-1 is capable of forming
chains through non-consensus lysines [28], albeit to a far lesser
extent compared to SUMO-2 and SUMO-3 [27]. The physio-
logical relevance of such poly-SUMO-1 chains is unclear [29], and
SUMO-1 itself may be more involved in chain termination of
SUMO-2 and SUMO-3 rather than formation in vivo [30]. Along
similar lines, the physiological significance of some sumoylation
sites observed by Okada et al. using sumo-engineered E. coli is also
unclear [25].
Here, we engineered an E3-dependent SUMO-conjugation
system in E. coli that employs members of the mammalian PIAS
E3 ligase family and, as a result, involves no observable poly-
sumoylation of target proteins. Furthermore, because E. coli lacks
organelles and an endogenous sumoylation pathway, our system
provides an alternative in vivo context that is insulated from factors
such as target localization, downstream interactions, and the
diversity of sumoylated proteins that confound studies of E3s in
eukaryotic cells. Finally, we show that addition of the E3 increases
the efficiency of sumoylation, yielding as much as ,5 mg/L of
SUMO-modified proteins. This makes possible greater titers of
specifically sumoylated target proteins for use in biochemical and
structural characterization.
Results
A Tunable E3-dependent Sumoylation System
To establish a SUMO-conjugation cascade in E. coli, the
bacterial pZ vector system developed by Lutz and Bujard [31] was
used. We chose the pZ vector system because of its modular
nature, unique promoters, and medium to low copy number.
Previous studies showed that strong expression of the E1 (human
Aos1 and Uba2) and E2 (murine Ubc9) enzymes in E. coli results in
sumoylation that is independent of the SUMO E3 ligase [11].
However, poly-sumoylated target evolves alongside mono-sumoy-
lated product. To generate only mono-sumoylated target proteins,
we attempted to reduce the expression of the E1 and E2 enzymes
by placing the genes encoding human E1 and murine E2 into the
medium copy vector pZA31-SMCS or the low copy vector pZS31-
SMCS (Fig. 1a). To maximize sumoylated product, human
SUMO-1 and the target protein were placed in the high copy
vector pZE11-SMCS (Fig. 1a). A FLAG epitope tag was
introduced to the C-terminus of the target protein to facilitate
Western blot analysis. SUMO E3 ligases were placed on a separate
plasmid, pZA24-SMCS, with a compatible replication of origin,
p15A (Fig. 1a). The separate plasmid enables introduction of
modifications to the E3 protein without altering the rest of the
cascade components. Additionally, the Plac/ara promoter allows
modulation of the E3 expression level without impact upon the
remaining components.
We first investigated the bacterial expression of several
mammalian SUMO E3 ligases. Specifically, four enzymes from
the PIAS family were tested (PIAS1, PIASxb, PIAS3, and PIASy).
Of these, PIASxb was expressed most efficiently (Fig. 1b; data for
PIASxb and PIASy only); hence, we chose this E3 for further
study. The synthetic GST-PML target of Mencı ´a and de Lorenzo
was chosen as a model target substrate for our E3-dependent
SUMO-conjugation system [11]. This substrate is comprised of
E. coli glutathione S-transferase (GST) that has been C-terminally
modified with the 10-residue consensus sumoylation site from the
promyelocytic leukemia (PML) protein. Previous studies using
E. coli showed that this target can be sumoylated in an E3-
independent manner [11]. In a similar fashion, we observed that
when the E1 and E2 enzymes were expressed from the medium
copy pZA31-SMCS vector in the absence of the E3, a slower
migrating GST-PML band was detected (Fig. 2a, lane 3) but
disappeared when the E1 and E2 were also absent (Fig. 2a, lane 2).
Several lines of evidence indicate that this higher band is GST-
PML that has become sumoylated in an E3-independent manner.
First, this band migrated with an ,20-kDa upshift compared to
the unmodified GST-PML protein, which is consistent with the
roughly ,20-kDa shift previously reported for SUMO-1 [32].
Second, it reacted with anti-SUMO-1 antibodies (Fig. 2b, lane 3).
Next, we lowered the expression level of the E1 and E2 enzymes
by inducing each from the low-copy pZS31-SMCS plasmid (Fig.
S1). Under these conditions, the slower migrating band disap-
peared (Fig. 2a, lane 4). Given that a faint band was detectable
upon probing with anti-SUMO-1 antibodies (Fig. 2b, lane 4), we
conclude that sumoylation efficiency was drastically reduced under
these conditions. Upon introduction of the SUMO E3 ligase
PIASxb? sumoylated GST-PML reappeared under conditions
where the E1 and E2 were expressed from the low copy vector
(Fig. 2a and b, lane 5 in each). Thus, by lowering the expression
levels of the E1 and E2 enzymes and by adding a functional E3
enzyme, we successfully created an E3-dependent sumoylation
cascade in E. coli. It is particularly noteworthy that the efficiency of
sumoylation appeared to increase with the addition of PIASxb
(Fig. 2a or b, compare lanes 4 and 5). Although undetectable with
anti-GST antibodies, a faint band above the mono-sumoylated
GST-PML was observed using anti-SUMO-1 antibodies (Fig. 2b,
lane 5). This band likely arises from GST itself becoming weakly
sumoylated as has been previously reported [25]. The anti-
SUMO-1 antibodies also revealed a ,30-kDa band (Fig. 2b, lanes
3 and 5) that likely corresponds to a degradation product of the
sumoylated target, a native E. coli protein that has become
sumoylated, or a free di-SUMO-1 chain.
Mono-sumoylation of Target Proteins by E3-dependent
SUMO Modification System
In the earlier study of Mencı ´a and de Lorenzo, E3-independent
sumoylation in engineered E. coli resulted in modification of target
proteins with SUMO-1 chains [11]. To more carefully investigate
whether target proteins in our sumoylation system were poly-
sumoylated, we converted the green fluorescent protein (GFP) to
a sumoylation substrate by fusion to the PML tag. Since GFP does
not contain any predicted sumoylation sites, mono- versus poly-
sumoylation of the GFP-PML chimera can be used to assess
SUMO-1 chain formation on target proteins. Indeed, expression
of GFP without the PML tag in the E3-dependent (Fig. 3a and b,
lane 3 in each) and E3-independent (Fig. 3a and b, lane 6 in each)
systems resulted in no detectable target sumoylation. Likewise, no
sumoylation was detected for the GFP-PML chimera when the
lysine in the PML tag was mutated to arginine (Fig. 3a and b, lane
5 in each). On the other hand, expression of GFP-PML in the
Synthetic Sumo-Engineered E. coli
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cascades resulted in a clear band corresponding to mono-
sumoylated GFP-PML. For the E3-dependent system, the yield
of mono-sumoylated GFP-PML was ,5 mg/L of culture (Fig. S2).
Interestingly, a band corresponding in mass to di-SUMO-1
conjugated to GFP-PML was observed for the E3-independent
but not the E3-dependent system (Fig. 3a and b, compare lanes 4
and 7 in each), suggesting that the addition of the E3 and/or the
reduced expression of the E1 and E2 prevented poly-sumoylation.
It is noteworthy that a rather faint ,30 kDa band was detected
with anti-SUMO-1 antibodies, similar to that seen above in the
GST-PML experiments. Since this band did not depend on the
presence of the target substrate (Fig. 3b, lanes 2, 3 and 6), we
conclude that this band is not a degradation product of the
sumoylated target. It is also noteworthy that the intensity of this
band increased when the E1 and E2 were expressed from the
Figure 1. An E3-dependent sumoylation system. (a) Plasmid diagrams for the E3-dependent sumoylation system based on the pZ vector
collection. The E1 (Aos1 and Uba2) and E2 (Ubc9) were cloned into the low copy plasmid pZS31-SMCS or the medium copy pZA31-SMCS (not shown);
the E3 (e.g., PIASxb) was cloned into the medium copy plasmid pZA24-SMCS; the target protein (e.g., Smad4-FLAG) and SUMO-1 were cloned into the
high copy plasmid pZE11-SMCS. (b) Western blot analysis of cell lysate prepared from DH5a-Z1 cells expressing native and engineered SUMO E3
ligases as indicated. A much longer exposure time was required to visualize PIASy (lane 8). Control cells carried the empty pZE12-SMCS vector (lane
1). Blots were probed with anti-FLAG antibodies or anti-DnaK antibodies, with the latter serving as a loading control. (c) Schematic of the E3 chimeras
and truncation mutant tested in this study. Chimeras were created by swapping different domains between human PIASxb and PIASy using the
inserted restriction sites.
doi:10.1371/journal.pone.0038671.g001
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and 7).
Conjugation of SUMO-1 to a Natural Sumoylation
Target Protein
Next, we investigated whether our sumo-engineered E. coli
could conjugate SUMO-1 to a naturally occurring target of the
human sumoylation machinery. We chose the human tumor
suppressor protein Smad4, a central intracellular signal transducer
for transforming growth factor-b (TGF-b) signaling, whose
transcriptional potential is regulated by sumoylation [32,33].
Similar to our results above, expression of the E1 and E2 from
a medium copy vector resulted in E3-independent sumoylation of
Smad4 (Fig. 4a and b, lane 10 in each) whereas expression of the
E1 and E2 from a low-copy plasmid resulted in virtually no
detectable Smad4 sumoylation (Fig. 4a and b, lane 9 in each).
However, co-expression of the E1 and E2 from a low copy vector
along with the E3 resulted in strong sumoylation of Smad4 (Fig. 4a
and b, lane 7 compared to 1–6). As with the synthetic GST-PML,
sumoylation of Smad4 appeared to be more efficient in the
presence of the E3 (Fig. 4a and b, compare lanes 7 and 9). The
major sumoylation site in Smad4 is the consensus lysine at position
159 [32,34]. Mutation of this lysine residue to arginine (K159R)
abolished Smad4 sumoylation (Fig. 4a, lane 8). To verify that
K159 is the major site of SUMO attachment in our system, we
performed MALDI-TOF mass spectrometry (MS) analysis on the
SUMO-Smad4 band, which was purified on a Ni-NTA column
and separated from unmodified Smad4 by SDS-PAGE. As
expected, nearly all of the Smad4 was sumoylated at the consensus
K159 (Fig. S3).
An even higher molecular weight band relative to SUMO-
Smad4 was also produced in our sumo-engineered E. coli (Fig. 4a
and b, lane 7 in each). This band might correspond to the
attachment of SUMO-1 to a minor site on Smad4 or to the
formation of SUMO-1 chains on Smad4. We favored the former
possibility for two reasons. First, low-level expression of the E1 and
E2 along with the E3 promoted mono-sumoylation in the case of
GFP-PML. Consistent with this result, MS analysis of SUMO-
Smad4 failed to reveal evidence for the formation of SUMO-1
chains at either K16 or K17 of the already conjugated SUMO-1
(data not shown). Second, a faint sumoylation band was observed
for Smad4(K159R) (Fig. 4b, lane 8). Indeed, a known minor site of
sumoylation on Smad4 is the non-consensus K113 residue [32,34].
However, MS analysis did not provide any evidence for SUMO-1
conjugation at this position (data not shown). Thus, taken together,
we suspect that another lysine is sumoylated on this higher
molecular weight Smad4 species; however, at present the identity
of this lysine remains undetermined.
Functional Characterization of SUMO E3 Ligase Chimeras
The generation of chimeras, truncations, and mutants of the
Siz/PIAS protein family has provided great insight into the
function of each protein [10,35]. These alterations may impact
localization, interaction with local cellular factors, and recognition
of the target protein. However, decoupling these differences to
deduce function can be difficult in the eukaryotic cellular
environment. We hypothesized that our sumo-engineered E. coli
could be useful for understanding the SUMO-conjugation activity
of different E3 chimeras because it is devoid of the aforementioned
complications. To test this notion, we constructed several SUMO
E3 ligase variants. These included chimeras that were generated
by swapping the SAP (scaffold attachment factor-A/B, acinus and
PIAS), PINIT, or SP-RING (Siz/PIAS really interesting new gene)
domains between PIASxb and PIASy, and a truncation mutant
that was made by eliminating the C-terminal tail of PIASxb
(Fig. 1c). Although PIASy expression could only be seen after
a much longer exposure time compared to PIASxb (Fig. 1b), its
expression was second most efficient among all PIAS family
members that were tested. Hence, we chose to use PIASy in our
chimeric constructs. A panel of E3 variants which all contain the
N-terminal SAP domain from PIASxb were observed to express
on par with PIASxb (Fig. 1b). Since PIASy also sumoylates Smad4
[36], we predicted that each of these variants would sumoylate
Smad4. In line with our hypothesis, all of the E3 variants
conjugated SUMO to Smad4, albeit to varying extents (Fig. 5a
and b, lanes 5–8 in each). None were as efficient as PIASxb; the
Pxb-Py(RING)-Pxbchimeraappeared to be the least efficient
(Fig. 5a and b, lanes 7 in each). Taken together, these data reveal
Figure 2. E3-dependent sumoylation of synthetic GST-PML.
Western blot analysis of cell lysate prepared from DH5a-Z1 cells
expressing the synthetic target GST-PML in the presence (+) or absence
(-) of different SUMO-conjugation cascade components. The E1 and E2
enzymes were expressed from either the medium copy plasmid pZA31-
SMCS (++) or the low-copy plasmid pZS31-SMCS (+). GST-PML was
detected using anti-GST antibodies (a) while SUMO-1 was detected
using anti-SUMO-1 antibodies (b). Detection of endogenous DnaK with
anti-DnaK antibodies served as a loading control.
doi:10.1371/journal.pone.0038671.g002
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functional evaluation of native as well as engineered SUMO E3
ligases.
Discussion
In this study, we have created the first E3-dependent
sumoylation system in E. coli. We anticipate that sumo-engineered
E. coli will be useful in further studies of the sumoylation
mechanism for several reasons. First, greater yields of sumoylated
proteins for biochemical and structural analysis should be
attainable through the addition of an E3 [13,34]. Indeed, for
both GST-PML and Smad4 substrates, we observed an increase in
sumoylation efficiency following the addition of a functional E3 to
the system. Furthermore, by lowering the expression of the E1 and
E2, additional cellular resources can be diverted towards pro-
duction of the target protein. Even without any process
optimization, our E3-dependent SUMO conjugation system
yielded ,5 mg/L of mono-sumoylated protein. Second, the
system enables functional characterization of any of the sumoyla-
tion cascade enzymes while eliminating the concern for localiza-
tion, downstream interactions, and the diversity of sumoylated
proteins that can obscure similar analysis in eukaryotic hosts. Our
system also produces physiologically relevant results. For instance,
we observed that Smad4 was sumoylated primarily at K159,
which is reported to be the major sumoylation site [32,34]. We did
not detect sumoylation at position K113, which was reported as
a minor site of sumoylation in one report [32] but was not
sumoylated in another [37]. We also did not detect SUMO-1
chains on target proteins in our E3-dependent system, which is in
stark contrast to an earlier bacterial E3-independent sumoylation
system [11]. It should be noted, however, that the inability of MS
analysis to reveal poly-sumoylation via K16 and K17 linkages on
SUMO-1 could arise from low abundance and/or poor ionization
efficiency of these species. Nonetheless, based on the high-intensity
MS signal detected for the K159 SUMO-1 peptide, we conclude
that no appreciable quantities of SUMO-1 chains are present.
Overall, our system yields results that are entirely consistent with
Figure 3. E3-dependent sumoylation of synthetic GFP-PML. Western blot analysis of cell lysate prepared from DH5a-Z1 cells expressing the
synthetic target GFP-PML in the presence (+) or absence (-) of different SUMO-conjugation cascade components. The E1 and E2 enzymes were
expressed from either the medium copy plasmid pZA31-SMCS (++) or the low-copy plasmid pZS31-SMCS (+). GFP was detected using anti-GFP
antibodies (a), while SUMO-1 was detected using anti-SUMO-1 antibodies (b). K490 refers to the lysine’s native location within PML rather than its
location within GFP-PML. Detection of endogenous DnaK with anti-DnaK antibodies served as a loading control.
doi:10.1371/journal.pone.0038671.g003
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show that engineered E3 variants can be expressed and
functionally characterized in our system. This is significant
because our bacterial SUMO-conjugation system provides a po-
tentially less convoluted background for studying sumoylation.
While in vitro reconstitution studies could also be used to eliminate
these factors, our system obviates the need for purification of each
cascade component and the corresponding need to modify each
cascade component with a purification tag, which can affect
enzyme function. Thus, we anticipate that our sumo-engineered
E. coli system will be a useful new tool for illuminating the
molecular details of the SUMO-conjugation process.
Materials and Methods
Plasmid Construction
All plasmids were based on the pZ vector system developed by
Lutz and Bujard [31]. Primer insertions were used to replace the
multiple cloning site (MCS) between the restriction sites EcoRI and
XbaI in the plasmids pZE12, pZE11, pZA24, and pZS31. The
resulting vectors - pZE12-SMCS, pZE11-SMCS, pZA24-SMCS,
and pZS31-SMCS - consisted of three pairs of restriction sites
(KpnI and SphI, MluI and EagI, and KasI and ClaI) with each pair
flanked by a strong RBS sequence (59 – AAAGAGGAGAAA –39)
and a frame-shifted stop codon sequence (59 – TAATTGAA-
TAGTTAA –39) to prevent translational read-through. For any
vector where these sites were not unique, we first cloned the genes
into the modified pZE12 vector prior to moving the fragment
generated by digestion with KpnI and ClaI into the appropriate
final vector. To make pZS31-Ubc9, pZS31-Aos1.Uba2, and
pZS31-Aos1.Uba2.Ubc9, the genes encoding human Aos1,
human Uba2, and murine Ubc9 were PCR amplified from
pBADE12 [11]. The resulting PCR products were then inserted
into pZS31-SMCS. For pZA31-Aos1.Uba2.Ubc9, pZS31-Aos1.U-
ba2.Ubc9 was cut at XhoI and ClaI and moved into pZA24-SMCS.
The plasmid’s selection marker was changed to chloramphenicol
using the restrictions sites SpeI and XhoI. A FLAG epitope tag for
Western blot detection was introduced to Aos1 by adding the
FLAG DNA sequence (59 – GACTACAAGGACGATGACGA-
CAAGGGA –39) to the 39 primer during PCR amplification. A
36-FLAG epitope tag was added to Uba2 and Ubc9 using BsaI
and primer annealing of 59– CTCAGACTACAAAGACCAT-
GACGGTGATTATAAAGATCATGACATCGACTACAAG-
Figure 4. E3-dependent sumoylation of human Smad4. Western blot analysis of cell lysate prepared from DH5a-Z1 cells expressing human
Smad4 or Smad4(K159R) (mut) in the presence (+) or absence (-) of different SUMO-conjugation cascade components. The E1 and E2 enzymes were
expressed from either the medium copy plasmid pZA31-SMCS (++) or the low-copy plasmid pZS31-SMCS (+). Smad4 was detected using anti-FLAG
antibodies (a), while SUMO-1 was detected using anti-SUMO-1 antibodies (b). Detection of endogenous DnaK with anti-DnaK antibodies served as
a loading control.
doi:10.1371/journal.pone.0038671.g004
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TACTTGTCATCGTCATCCTTGTAGTCGATGTCAT-
GATCTTTATAATCACCGTCATGGTCTTTGTAGTC –39.
To generate the plasmids pZE11-GST-PML.SUMO, pZE11-
Smad4-FLAG, pZE11-SUMO and pZE11-Smad4-FLAG.-
SUMO, GST-PML and human Smad4 were PCR amplified
from pGST-PML [11] and pOTB7-Smad4 [40], respectively, and
inserted between KpnI and SphI of pZE11-SMCS. DNA encoding
a FLAG epitope tag was added C-terminally to Smad4 during
PCR amplification. Human SUMO-1 was PCR amplified from
pKRSUMO [11] and inserted between MluI and EagI. The
restriction site BsaI was used to create the Smad4(K159R) mutant.
To generate pZE11-GFP.SUMO, pZE11-GFP-PML.SUMO, and
pZE11-GFP-PML(K490R).SUMO, GFP was PCR amplified and
Figure 5. Chimeric E3-dependent sumoylation of human Smad4. Western blot analysis of cell lysate prepared from DH5a-Z1 cells expressing
human Smad4 in the presence (+) or absence (-) of different SUMO-conjugation cascade components. The E1 and E2 enzymes were expressed from
either the medium copy plasmid pZA31-SMCS (++) or the low-copy plasmid pZS31-SMCS (+). PIASxb (lane 4) as well as a panel of E3 variants (lanes 5–
8; see Fig. 1c caption for details) were tested for functionality. Smad4 was detected using anti-FLAG antibodies (a), while SUMO-1 was detected using
anti-SUMO-1 antibodies (b). Detection of endogenous DnaK with anti-DnaK antibodies served as a loading control.
doi:10.1371/journal.pone.0038671.g005
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two cases, DNA encoding PML or PML(K490R) was added C-
terminally to GFP during PCR amplification. To construct
pZA24-PIASxb and pZA24-PIASy, PIASxb and PIASy were
PCR amplified from pCMV-FLAG-hPIASxb [38] and pCMV-
FLAG-hPIASy [39], respectively, and inserted between KpnI and
SphI of pZA24-SMCS. To facilitate Western blot analysis, a FLAG
epitope tag was added C-terminally to all of the E3s during PCR
amplification.
To assemble the SUMO E3 ligase chimeras, fragments of
PIASxb and PIASy were PCR-amplified and restriction sites
introduced during PCR amplification. The restriction sites were
placed in predicted unstructured regions [41] that flanked
a domain of interest and made use of silent mutations when
possible to preserve the amino acid sequence. The restriction sites
NotI, SpeI, BamHI, and NheI were inserted after K79, L299, V436,
and Q508 in PIASxb, and after P77, L279, G440, and A509 in
PIASy. Fragments containing these restriction sites were PCR
amplified and then ligated together in plasmid pZE12-SMCS
before being moved to pZA24-SMCS. PIASxb was truncated after
Q508 to create the PIASxb truncation variant.
Cell Growth and Western Blot Analysis
All constructs were transformed into E. coli host strain DH5a-Z1
[31] using a GenePulser Xcell (BioRad). Individual colonies were
grown overnight in LB media with appropriate antibiotics
(100 mg/mL ampicillin, 40 mg/mL kanamycin, and 12.5 mg/mL
chloramphenicol) and then subcultured to OD600 < 0.05 in 5 mL
of fresh LB media supplemented with appropriate antibiotics.
Cultures were induced at OD600 < 0.75 with 0.5% L(+)-arabinose,
1 mM IPTG, and 50 ng/mL anhydrotetracycline when appro-
priate and subsequently shaken for 24 h at 16uCo r2 5 uC
depending on determined optimal conditions for sumoylation.
Approximately 1.5 mL of each culture was harvested and lysed
using 200 mL of Bugbuster Master Mix (Novagen) according to the
manufacturer’s directions. Lysates were normalized to 10 mgo f
total protein as determined by a total protein assay (Bio-Rad) and
loaded on a 4–20% Precise Protein Gel (Thermo Scientific).
Transfers to Immobilon P Transer Membranes (Millipore) were
performed for 2 h at the maximum amperage recommended for
a Biosciences TE77 semi-dry transfer unit (Amersham). Blots were
then imaged on film using standard protocols. The primary
antibodies used were anti-GST (Abcam), anti-FLAG (Abcam),
anti-GFP (Roche), anti-SUMO-1 (Abcam), and anti-DnaK
(Stressgen). A standard curve was generated with purified GFP
(AbCam) and used to quantify the yield of sumoylated GFP-PML.
Densitometry analysis was performed on a Macintosh computer
using the public domain NIH Image program (developed at the
U.S. National Institutes of Health and available on the Internet at
http://rsb.info.nih.gov/nih-image/).
Protein Purification
Overnight cultures were subcultured into 250 mL of fresh LB
media with appropriate antibiotics. At OD600 < 0.5, cultures were
induced as described above and shaken for 3 h at 37uC. Cells were
then pelleted using a J2–21 floor centrifuge (Beckman) and lysed
using Bugbuster Master Mix (Novagen). Samples were purified
using Ni-NTA spin columns (Qiagen) according to the manufac-
turer’s instructions. Purification was not optimized.
In-gel Digestion of Excised Gel Bands
Following visualization of the SDS-PAGE gel, two visible
protein bands of interest were excised, diced, and placed into
microtubes for the subsequent in-gel digestion and extraction. The
in-gel digestion by chymotrypsin (from Sigma, St. Louis, MO) and
the subsequent peptide extraction were performed following
a protocol from Yang, et al. [42] with slight modification. The
gel pieces were washed and destained with a series of solutions:
50 mL of water, 50 mL of 50% ACN/50% 50 mM ammonium
bicarbonate pH 7.8, and 50 mL of 100% ACN. The samples were
reduced with DTT and alkylated by treatment with iodoaceta-
mide. Once the samples were dried down completely after
washing, ,0.2 mg LysC or chymotrypsin in 20 mLo f5 0m M
ammonium bicarbonate (pH =7.8) and 10% ACN was added to
each tube. The samples were left on ice for 15 min and incubated
overnight at 37uC. The supernatant containing digested peptides
was removed after centrifuging for 2 min at 40006 g, and the
remaining peptides were then extracted from the gel in a series of
extraction steps. The first was with 30 mL of 25 mM ammonium
bicarbonate pH 7.8 (30 minutes). Two sequential steps each with
50 mL of 5% formic acid in 50% acetonitrile (10 min) followed.
For each extraction, the sample was sonicated for 5 min before the
supernatant was removed. All gel-extracted supernatants were
combined and evaporated to dryness in a Speedvac SC110
(Thermo Savant, Milford, MA).
Protein Identification by nanoLC/MS/MS Analyses
The tryptic digest was reconstituted in 15 mL of 2% ACN with
0.5% FA for nanoLC-ESI-MS/MS analysis, which was carried
out using a LTQ-Orbitrap Velos (Thermo-Fisher Scientific, San
Jose, CA) mass spectrometer equipped with a nano ion source
device (CorSolutions LLC, Ithaca, NY). The Orbitrap is interfaced
with an UltiMate3000 MDLC system (Dionex, Sunnyvale, CA).
The nanoLC was carried out by Dionex UltiMate3000 MDLC
system (Dionex, Sunnyvale, CA). An aliquot of tryptic peptide
(3.0 mL) was injected onto a PepMap C18 trap column (5 mm,
300 mm 65 mm, Dionex) at a 20 mL/min flow rate for on-line
desalting. It was then separated on a PepMap C-18 RP
nanocolumn (3 mm, 75 mm615 cm) and eluted in a 60 min
gradient of 5% to 38% acetonitrile (ACN) in 0.1% formic acid at
300 nL/min followed by a 3-min ramping to 95% ACN-0.1%FA
and a 5-min holding at 95% ACN-0.1%FA. The column was re-
equilibrated with 2% ACN-0.1%FA for 20 min prior to the next
run. The eluted peptides were detected by an Orbitrap through
the nano ion source containing a 10-mm analyte emitter (New-
Objective, Woburn, MA). The Orbitrap Velos was operated in
positive ion mode with nanospray voltage set at 1.6 kV and source
temperature at 225uC. Either internal calibration using the
background ion signal at m/z 445.120025 as a lock mass or
external calibration for FT mass analyzer was performed. The
instrument was run at data-dependent acquisition (DDA) mode
using FT mass analyzer for one survey MS scan followed by MS/
MS scans on the five most intense peaks with multiple charged
ions above a threshold ion count of 5000. MS survey scans were
acquired at a resolution of 60,000 (fwhm at m/z 400) for the mass
range of m/z 400–1400, and MS/MS scans were acquired at
7,500 resolution for the mass range of m/z 100 to 2000. Dynamic
exclusion parameters were set at repeat count 1 with a 20 s repeat
duration, exclusion list size of 500, 30 s exclusion duration, and
610 ppm exclusion mass width. High energy dissociation (HCD)
parameters were set at the following values: isolation width 2.0 m/
z, normalized collision energy 45%, and activation time 0.1 ms.
Xcalibur 2.1 operation software (Thermo-Fisher Scientific) was
used to acquire all data.
Data Analysis
All MS and MS/MS raw spectra were processed using
Proteome Discoverer 1.1 (PD1.1, Thermo). The spectra from
Synthetic Sumo-Engineered E. coli
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precursor ions of interest and their MS/MS spectra. The mass
accuracy for all identified peptides is within 2 ppm.
Supporting Information
Figure S1 Decreasing plasmid copy number reduces E1
and E2 expression levels. (Top panels) Western blot analysis
of cell lysate prepared from DH5a-Z1 cells expressing human
Aos1 and Uba2 and murine Ubc9 from either the medium copy
plasmid pZA31-SMCS (A) or the low-copy plasmid pZS31-SMCS
(S). The protein name heading each column indicates the moiety
bearing the epitope tag. Aos1 and Uba2 each bear a FLAG
epitope tag while Ubc9 bears a 36FLAG epitope tag as a single
FLAG epitope was insufficient for detection. (Bottom panels) Same
gel as in (a) but longer exposure time.
(PDF)
Figure S2 Quantification of sumoylated GFP-PML by
Western blot and densitometry analysis. The amount of
SUMO-GFP-PML produced by the entire sumoylation cascade
(low copy expression of E1 and E2 plus the E3) was determined by
direct comparison to known quantities of purified GFP standard as
indicated. Densitometry analysis was performed on a Macintosh
computer using the public domain NIH Image program (de-
veloped at the U.S. National Institutes of Health and available on
the Internet at http://rsb.info.nih.gov/nih-image/).
(PDF)
Figure S3 (First panel) MS spectrum of Smad4 chymotryptic
digests acquired in the FT analyzer of the Orbitrap Velos during
the nanoLC-MS/MS analysis at elution time =23.71 min. A
base-peak doubly-charged precursor ion at m/z 1109.9631 with its
triply-charged ion at m/z 740.3111 shown in expanded view of
insets is identified as sumoylated peptide. Sequence for the Smad4
peptide (red) with the conjugated SUMO-1 peptide (blue) after
chymotrypsin digestion is shown. Lower case m indicates the
oxidized methionine. The survey MS scan shows that the mass of
the detected sumoylated peptide at K159 is under 1.8 ppm of its
calculated mass. (Second panel) MS/MS spectrum of a triply-
charged ion at m/z 740.31
3+ acquired in HCD-DDA analysis by
the FT analyzer at 23.90 min derived from Smad4 residues 149 to
162 with K159 identified as the sumoylated site. The y- and b-type
ions are labeled in the spectrum as blue and red color for the
SUMO-1 and the Smad4 target peptides, respectively. (Third
panel) MS/MS spectrum of 1109.96
2+ ion eluted at 23.84 min for
identification of K159 sumoylation.
(PDF)
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